Curia

Patients

The UK faces one of the largest gender health gaps among G20 nations and women’s health challenges remain significantly, unacceptably underserved.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.